Insider got exclusive access to bankruptcy-risk ratings to identify vulnerable biotechs. The biotech market has dropped 42% this year, putting cash-starved or debt-laden firms at risk. The firm ...

Biotech companies have always licensed programs, but never so many from one region in particular.

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched ...

Biotechnology advances offer immense public health and consumer potential, but come with serious risks. A recent workshop held by the Council on Foreign Relations brought experts together to discuss ...

Jonathan Faison first started exploring the biotech space a decade ago. He emphasizes a focus on preserving capital by limiting position sizes and picking stocks that have multiple "irons in the fire" ...

Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...